Ascletis Pharma Inc.
Ascletis Pharma is a Hangzhou-based, Hong Kong-listed (HKEX: 1672) drug developer concentrating on obesity and chronic weight management. Its lead candidate ASC30 is in a multinational Phase 3 programme that includes the United States, and the company is presenting data on ASC48 and ASC37 at ObesityWeek 2026.
| Headquarters | Hangzhou, China |
|---|---|
| Listing | HKEX:01672 |
| Lead asset / stage | ASC30 Phase 3 — multinational (including United States) |
| Latest event | Ascletis announced ASC48 and ASC37 study results for presentation at ObesityWeek 2026. |